Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure
American Journal of Translational Research · 2026 · 18 (10) · 9530-9541
DOI: 10.62347/cqek6090 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Yabing Cao und 7 weiteren Autor:innen.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Cao, Y., Sun, Y., Miao, B., Zhang, X., Zhao, Q., Qi, L., Chen, Y., & Zhu, L. (2026). Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure. American Journal of Translational Research, 18(10), 9530-9541. https://doi.org/10.62347/cqek6090
Vancouver
Cao Y, Sun Y, Miao B, Zhang X, Zhao Q, Qi L, et al. Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure. American Journal of Translational Research. 2026;18(10):9530-9541. doi:10.62347/cqek6090
BibTeX
@article{Cao2026,
author = {Cao, Yabing and Sun, Yunjing and Miao, Bo and Zhang, Xiao and Zhao, Qingzhou and Qi, Liping and Chen, Yaoqi and Zhu, Lingling},
title = {Vericiguat combined with standard therapy improves cardiac function, inflammatory markers, and exercise tolerance in patients with essential hypertension and chronic heart failure},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {10},
pages = {9530--9541},
doi = {10.62347/cqek6090}
}
EUVIMED